Journal
MEDICINA CLINICA
Volume 145, Issue 2, Pages 76-83Publisher
ELSEVIER ESPANA SLU
DOI: 10.1016/j.medcli.2014.05.023
Keywords
Alzheimer's disease; New therapies; Immunotherapy; Vaccine; Amyloid-beta
Categories
Ask authors/readers for more resources
The rapid increase in prevalence rates of Alzheimer's disease means that treatments to prevent, stop or reverse this devastating disease are urgently needed. Despite advances in understanding its molecular pathology, there are no drugs that can halt its progression. This review takes a tour through phase 2, or higher studies, probing receptor agonist agents interfering with aggregation, inhibitors/modulators of secretases, lipid-lowering agents, and, finally and most extensively, immunotherapy. The fact that phase 3 studies with bapineuzumab and solaneuzumab have recently failed does not invalidate the potential of immunotherapy, as more information is available and new clinical trials are being initiated. (c) 2014 Elsevier Espana, S.L.U. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available